Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety.

Benzil has been identified as a potent selective inhibitor of carboxylesterases (CEs). Essential components of the molecule required for inhibitory activity include the dione moiety and the benzene rings, and substitution within the rings affords increased selectivity toward CEs from different species. Replacement of the benzene rings with heterocyclic substituents increased the K(i) values for the compounds toward three mammalian CEs when using o-nitrophenyl acetate as a substrate. Logarithmic plots of the K(i) values versus the empirical resonance energy, the heat of union of formation energy, or the aromatic stabilization energy determined from molecular orbital calculations for the ring structures yielded linear relationships that allowed prediction of the efficacy of the diones toward CE inhibition. Using these data, we predicted that 2,2'-naphthil would be an excellent inhibitor of mammalian CEs. This was demonstrated to be correct with a K(i) value of 1 nM being observed for a rabbit liver CE. In addition, molecular simulations of the movement of the ring structures around the dione dihedral indicated that the ability of the compounds to inhibit CEs was due, in part, to rotational constraints enforced by the dione moiety. Overall, these studies identify subdomains within the aromatic ethane-1,2-diones, that are responsible for CE inhibition.

[1]  P. Beroza,et al.  Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. , 2005, Journal of medicinal chemistry.

[2]  P. Beroza,et al.  Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. , 2004, Molecular pharmacology.

[3]  P. Beroza,et al.  Chemoproteomics as a basis for post-genomic drug discovery. , 2002, Drug discovery today.

[4]  M. Wierdl,et al.  Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. , 2001, Molecular pharmacology.

[5]  C. Morton,et al.  Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 cells for recombinant gene expression , 2000, Molecular biotechnology.

[6]  C. Morton,et al.  Proficient metabolism of irinotecan by a human intestinal carboxylesterase. , 2000, Cancer research.

[7]  M. Wierdl,et al.  Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. , 2000, Cancer research.

[8]  Steven L. Dixon,et al.  Investigation of classification methods for the prediction of activity in diverse chemical libraries , 1999, J. Comput. Aided Mol. Des..

[9]  D. V. Von Hoff,et al.  Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts. , 1999, Cancer research.

[10]  P. Houghton,et al.  Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  C. Morton,et al.  The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. , 1999, Cancer research.

[12]  Steven L. Dixon,et al.  Bioactive Diversity and Screening Library Selection via Affinity Fingerprinting , 1998, J. Chem. Inf. Comput. Sci..

[13]  M. Wierdl,et al.  Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. , 1998, Cancer research.

[14]  G. Vassal,et al.  Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Morton,et al.  Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). , 1998, Cancer research.

[16]  Louis J. Farrugia,et al.  ORTEP-3 for Windows - a version of ORTEP-III with a Graphical User Interface (GUI) , 1997 .

[17]  J Zhang,et al.  Purification and Cloning of a Broad Substrate Specificity Human Liver Carboxylesterase That Catalyzes the Hydrolysis of Cocaine and Heroin* , 1997, The Journal of Biological Chemistry.

[18]  Pinghua Ge,et al.  Poly(2-thienyl)borates: An Investigation into the Coordination of Thiophene and Its Derivatives. , 1996, Inorganic chemistry.

[19]  L. Rivory,et al.  IRINOTECAN (CPT‐11): A BRIEF OVERVIEW , 1996, Clinical and experimental pharmacology & physiology.

[20]  J R Cashman,et al.  Pharmacokinetics and molecular detoxication. , 1996, Environmental health perspectives.

[21]  W. Bosron,et al.  Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. , 1994, Biochemical pharmacology.

[22]  T. Satoh,et al.  Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. , 1994, Biological & pharmaceutical bulletin.

[23]  A. Székács,et al.  Hydrolysis of Carbonates, Thiocarbonates, Carbamates, and Carboxylic Esters of α-Naphthol, β-Naphthol, and p-Nitrophenol by Human, Rat, and Mouse Liver Carboxylesterases , 1993, Pharmaceutical Research.

[24]  James J. P. Stewart,et al.  MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..

[25]  J. Stewart Optimization of parameters for semiempirical methods I. Method , 1989 .

[26]  I. Silman,et al.  Microtiter assay for acetylcholinesterase. , 1987, Analytical biochemistry.

[27]  H. Flack,et al.  On enantiomorph‐polarity estimation , 1983 .

[28]  Michael J. S. Dewar,et al.  Ground states of conjugated molecules. XI. Improved treatment of hydrocarbons , 1969 .

[29]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[30]  M. Weiss,et al.  The catalytic oxidation of benzoin to benzil. , 1948, Journal of the American Chemical Society.

[31]  P. Potter,et al.  Enzyme-prodrug systems: carboxylesterase/CPT-11. , 2004, Methods in molecular medicine.

[32]  P. Potter,et al.  Enzyme-Prodrug Systems , 2004 .

[33]  M Hosokawa,et al.  The mammalian carboxylesterases: from molecules to functions. , 1998, Annual review of pharmacology and toxicology.

[34]  E. Cvitkovic,et al.  Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. , 1996, European journal of cancer.

[35]  A. Székács,et al.  Hydrolysis of carbonates, thiocarbonates, carbamates, and carboxylic esters of alpha-naphthol, beta-naphthol, and p-nitrophenol by human, rat, and mouse liver carboxylesterases. , 1993, Pharmaceutical research.

[36]  M. Dewar,et al.  Aromatic energies of some heteroaromatic molecules , 1989 .

[37]  A. Gordon,et al.  The Chemist's Companion: A Handbook of Practical Data, Techniques, and References , 1972 .

[38]  N. Trinajstic,et al.  Ground states of conjugated molecules—XIV: Redox potentials of quinones , 1965 .

[39]  John Leyden. Webb,et al.  Enzyme and metabolic inhibitors , 1963 .